| 摘要 |
<p>A method is provided for developing therapies to effectively treat sepsis and for studying the cellular and molecular mechanisms that result in sepsis, using an in vivo system comprised of transgenic non-human animal whose germ cells and somatic cells contain and express the human gene for the CD14 myelomonocytic differenctiation marker. The gene is introduced into an embryo of the non-human animal or of an ancestor of the non-human animal. The resulting non-human animal is characterized by a heightened sensitivity toward endotoxin-induced sepsis that is mediated by the gene product of the human CD14 gene.</p> |
